

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Michael J. Davies, et al.

:Examiner: To Be Assigned

SERIAL NO.: To Be Assigned

:Art Unit: To Be Assigned

FILED: Herewith

FOR: Treatment of Wounds

Assistant Commissioner For Patents  
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

In the matter of the application being filed herewith, please amend the application as follows, before calculating the filing fee:

In the specification:

Please enter the following sentence as the first paragraph in the specification, immediately following the title:

--This application is filed claiming priority from co-pending United States Provisional Application No. 60/232,669 filed September 15, 2000.--

In the Claims

Cancel claim 2 without waiver of prejudice.

3. (Amended) A method as claimed in claim 1, wherein the inhibitor is administered orally or topically.

4. (Amended) A method as claimed in claim 1, wherein the inhibitor has an IC50 at less than 100 nanomolar.

6. (Amended) A method as claimed in claim 1, wherein the inhibitor is sildenafil.

9. (Amended) A method of treating wounds in a patient which comprises treating the patient with an effective amount of a cGMP PDE5 inhibitor in combination with a matrix metalloprotease inhibitor (MMP), and/or a urokinase type plasminogen activator inhibitor (uPA), wherein the wound type is selected from the following types: chronic venous ulcers, chronic arterial ulcers, chronic decubitus and acute wounds.

10. (Amended) A method as claimed in claim 9, wherein the MMP is selected from the group comprising: inhibitors of MMP-3, MMP-12 and MMP-13.

EXPRESS MAIL NO. EL 911724217 US

09927344-031001  
FOOTED: 44E22660

A1

A2

A3

A4